1832 Asset Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

1832 Asset Management’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$333K	Sell	50,432 -9,568	-16%	-$66K	﹤0.01%	590
2026 Q1	$434K	Buy	60,000 +27,862	+87%	+$224K	﹤0.01%	589
2025 Q4	$243K	Buy	+32,138	New	+$198K	﹤0.01%	667

Other funds holding EPRX

Beutel, Goodman & Co Toronto, Ontario, Canada $12.7B AUM 12.76% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

1832 Asset Management's EPRX Position: Q2 2026 in Review

1832 Asset Management reduced its Eupraxia Pharmaceuticals (EPRX) stake by 16% in Q2 2026, selling an estimated $66K and leaving 50,432 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #590.

1832 Asset Management first reported a position in EPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $434K in Q1 2026. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

1832 Asset Management held 50,432 shares of Eupraxia Pharmaceuticals worth $333K as of Q2 2026.
1832 Asset Management sold 9,568 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $66K.
Eupraxia Pharmaceuticals made up ﹤0.01% of 1832 Asset Management's portfolio in Q2 2026, its #590 holding.
1832 Asset Management first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
1832 Asset Management's Eupraxia Pharmaceuticals position peaked at $434K in Q1 2026.
67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on 1832 Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.